Advertisement

Topics

Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

14:12 EST 11 Jan 2019 | OncLive

Nina Shah, MD, discusses the promise of bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma

Original Article: Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

NEXT ARTICLE

More From BioPortfolio on "Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement